|
DE69633196D1
(de)
*
|
1995-10-16 |
2004-09-23 |
Fujisawa Pharmaceutical Co |
Heterocyclische verbindungen als h+-atpasen
|
|
GB9712761D0
(en)
*
|
1997-06-17 |
1997-08-20 |
Chiroscience Ltd |
Quinolines and their therapeutic use
|
|
GB9824160D0
(en)
*
|
1998-11-04 |
1998-12-30 |
Darwin Discovery Ltd |
Heterocyclic compounds and their therapeutic use
|
|
US6262070B1
(en)
|
1998-11-04 |
2001-07-17 |
Darwin Discovery Ltd. |
Heterocyclic compounds and their therapeutic use
|
|
HRP20020158B1
(en)
*
|
1999-08-21 |
2007-08-31 |
Altana Pharma Ag |
Action of synergistic combination
|
|
AU1053501A
(en)
*
|
1999-11-02 |
2001-05-14 |
Ajinomoto Co., Inc. |
Polyazanaphthalene compound and medicinal use thereof
|
|
JP4603646B2
(ja)
*
|
1999-11-15 |
2010-12-22 |
富士フイルムファインケミカルズ株式会社 |
新規なジピリジル誘導体
|
|
US7217722B2
(en)
|
2000-02-01 |
2007-05-15 |
Kirin Beer Kabushiki Kaisha |
Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
|
|
GB0003256D0
(en)
*
|
2000-02-11 |
2000-04-05 |
Darwin Discovery Ltd |
Heterocyclic compounds and their therapeutic use
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
DE10035928A1
(de)
*
|
2000-07-21 |
2002-03-07 |
Asta Medica Ag |
Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
|
|
AU2001277731A1
(en)
*
|
2000-08-09 |
2002-02-18 |
Welfide Corporation |
Fused bicyclic amide compounds and medicinal use thereof
|
|
US6953774B2
(en)
|
2000-08-11 |
2005-10-11 |
Applied Research Systems Ars Holding N.V. |
Methods of inducing ovulation
|
|
JP2002300373A
(ja)
*
|
2001-03-30 |
2002-10-11 |
Minolta Co Ltd |
画像処理方法、画像処理装置、記録媒体及びプログラム
|
|
CA2447618A1
(en)
*
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
A composition for regenerative treatment of cartilage disease
|
|
WO2002094321A1
(en)
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
Compositions for promoting healing of bone fracture
|
|
EP1409481B1
(en)
|
2001-07-16 |
2006-10-04 |
Astrazeneca AB |
Quinoline derivatives and their use as tyrosine kinase inhibitors
|
|
EP1417204B1
(en)
*
|
2001-08-15 |
2006-01-18 |
E. I. du Pont de Nemours and Company |
Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
|
|
JP4532115B2
(ja)
|
2001-12-14 |
2010-08-25 |
メルク セローノ ソシエテ アノニム |
非ポリペプチドｃＡＭＰレベル調節剤を使用する排卵誘発方法
|
|
MY140561A
(en)
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
|
SE0200920D0
(sv)
*
|
2002-03-25 |
2002-03-25 |
Astrazeneca Ab |
Novel compounds
|
|
ES2195785B1
(es)
*
|
2002-05-16 |
2005-03-16 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
AU2002950217A0
(en)
|
2002-07-16 |
2002-09-12 |
Prana Biotechnology Limited |
8- Hydroxy Quinoline Derivatives
|
|
ES2211344B1
(es)
*
|
2002-12-26 |
2005-10-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
TWI324150B
(en)
*
|
2003-02-28 |
2010-05-01 |
Novartis Ag |
Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
|
|
EP1624893A2
(en)
|
2003-04-01 |
2006-02-15 |
Applied Research Systems ARS Holding N.V. |
Inhibitors of phosphodiesterases in infertility
|
|
PE20050211A1
(es)
*
|
2003-04-02 |
2005-04-27 |
Novartis Ag |
Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
|
|
WO2004105796A1
(en)
*
|
2003-05-29 |
2004-12-09 |
Astrazeneca Ab |
A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
|
|
WO2004105797A1
(en)
*
|
2003-05-29 |
2004-12-09 |
Astrazeneca Ab |
A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
|
|
KR20060037258A
(ko)
*
|
2003-05-29 |
2006-05-03 |
아스트라제네카 아베 |
Ｐ2Ｘ7-수용체 길항제 및 종양 괴사 인자 α를 포함하는제약 조성물
|
|
GB0312609D0
(en)
*
|
2003-06-02 |
2003-07-09 |
Astrazeneca Ab |
Novel compounds
|
|
SE0302139D0
(sv)
*
|
2003-07-28 |
2003-07-28 |
Astrazeneca Ab |
Novel compounds
|
|
SE0302192D0
(sv)
*
|
2003-08-08 |
2003-08-08 |
Astrazeneca Ab |
Novel compounds
|
|
JP2007505834A
(ja)
*
|
2003-09-15 |
2007-03-15 |
シェーリング コーポレイション |
Ｐｄｅｉｖインヒビターの調製のために有用なキノリン５−カルボキサミドの合成
|
|
SE0302488D0
(sv)
*
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
New combination
|
|
PA8619901A1
(es)
|
2003-12-12 |
2005-11-25 |
Wyeth Corp |
Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
|
|
EP2666481B9
(en)
|
2003-12-26 |
2019-05-22 |
HAGIWARA, Masatoshi |
Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
|
|
KR100799802B1
(ko)
|
2004-02-04 |
2008-01-31 |
화이자 프로덕츠 인크. |
치환된 퀴놀린 화합물
|
|
CA2561660C
(en)
*
|
2004-04-01 |
2012-10-30 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of pyrimidine-2,4,6-triones
|
|
JP4584990B2
(ja)
*
|
2004-05-18 |
2010-11-24 |
シェーリング コーポレイション |
Ｐｄｅ４インヒビターとして有用な置換２−キノリル−オキサゾール
|
|
ES2251866B1
(es)
*
|
2004-06-18 |
2007-06-16 |
Laboratorios Almirall S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
ES2251867B1
(es)
*
|
2004-06-21 |
2007-06-16 |
Laboratorios Almirall S.A. |
Nuevos derivados de piridazin-3(2h)-ona.
|
|
GB0413960D0
(en)
*
|
2004-06-22 |
2004-07-28 |
Novartis Ag |
Organic compounds
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
PT1773816E
(pt)
*
|
2004-06-24 |
2015-04-29 |
Vertex Pharma |
Moduladores de transportadores de cassete de ligação de atp
|
|
SA05260265A
(ar)
*
|
2004-08-30 |
2005-12-03 |
استرازينيكا ايه بي |
مركبات جديدة
|
|
KR101271372B1
(ko)
*
|
2004-10-12 |
2013-06-07 |
액테리온 파마슈티칼 리미티드 |
결정질 술페이트 염으로서의 1-〔2-(4-벤질-4-하이드록시-피페리딘-1-일)-에틸〕-3-(2-메틸-퀴놀린-4-일)-유레아
|
|
KR100867071B1
(ko)
*
|
2004-10-19 |
2008-11-04 |
에프. 호프만-라 로슈 아게 |
퀴놀린 유도체
|
|
SE0402925D0
(sv)
*
|
2004-11-30 |
2004-11-30 |
Astrazeneca Ab |
Novel Compounds
|
|
US8686002B2
(en)
|
2005-08-21 |
2014-04-01 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
|
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
|
US7678363B2
(en)
|
2005-08-26 |
2010-03-16 |
Braincells Inc |
Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
|
EP1979367A2
(en)
*
|
2005-12-24 |
2008-10-15 |
Vertex Pharmaceuticals Incorporated |
Quinolin-4-one derivatives as modulators of abc transporters
|
|
RS55940B1
(sr)
|
2005-12-28 |
2017-09-29 |
Vertex Pharma |
Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
|
|
KR100821649B1
(ko)
*
|
2006-01-24 |
2008-04-11 |
서울시립대학교 산학협력단 |
클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
CA2651813A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
RU2009104346A
(ru)
*
|
2006-07-11 |
2010-08-20 |
Шеринг Корпорейшн (US) |
Ксинафоатная соль замещенного 5-оксазол-2-ил-хинолинового соединения
|
|
EP2058310A4
(en)
|
2006-09-01 |
2010-11-17 |
Kyorin Seiyaku Kk |
PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE INHIBITOR (PDE) COMPRISING THE DERIVATIVE
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
CL2007003874A1
(es)
*
|
2007-01-03 |
2008-05-16 |
Boehringer Ingelheim Int |
Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
|
|
ES2306595B1
(es)
*
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
|
ES2320954B1
(es)
*
|
2007-03-02 |
2010-03-16 |
Laboratorio Almirall S.A. |
Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
|
|
ES2388454T3
(es)
*
|
2007-03-22 |
2012-10-15 |
Astrazeneca Ab |
Derivados de quinolina para el tratamiento de enfermedades inflamatorias
|
|
US9321730B2
(en)
|
2007-08-21 |
2016-04-26 |
The Hong Kong Polytechnic University |
Method of making and administering quinoline derivatives as anti-cancer agents
|
|
PE20091036A1
(es)
|
2007-11-30 |
2009-08-15 |
Astrazeneca Ab |
Derivado de quinolina como antagonista del receptor p2x7
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
EP2821400B1
(en)
|
2009-03-20 |
2017-09-27 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
JP2011042643A
(ja)
*
|
2009-07-24 |
2011-03-03 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
US8367829B2
(en)
|
2010-05-10 |
2013-02-05 |
Gilead Sciences, Inc. |
Bi-functional pyrazolopyridine compounds
|
|
US8394829B2
(en)
|
2010-05-10 |
2013-03-12 |
Gilead Sciences, Inc. |
Bi-functional quinoline analogs
|
|
WO2013074059A2
(en)
*
|
2010-11-05 |
2013-05-23 |
Regents Of The University Of Minnesota |
Cytosine deaminase modulators for enhancement of dna transfection
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN102603628B
(zh)
|
2010-12-22 |
2016-08-17 |
香港理工大学 |
作为抗癌试剂的喹啉衍生物
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
MX2014010253A
(es)
|
2012-02-27 |
2014-11-12 |
Vertex Pharma |
Composicion farmaceutica y administraciones de la misma.
|
|
CN103254291B
(zh)
*
|
2013-05-30 |
2014-06-25 |
常州亚当生物技术有限公司 |
肿瘤坏死因子-α多肽抑制剂及其应用
|
|
CN103285373A
(zh)
*
|
2013-05-30 |
2013-09-11 |
苏州普罗达生物科技有限公司 |
肿瘤坏死因子-α多肽抑制剂制备及其应用
|
|
WO2015057659A1
(en)
*
|
2013-10-14 |
2015-04-23 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
|
RU2624906C2
(ru)
*
|
2015-12-22 |
2017-07-10 |
федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Производные 2-хинальдинкарбоновой кислоты и их противогриппозная активность
|
|
CN111050558B
(zh)
|
2017-09-13 |
2022-05-27 |
先正达参股股份有限公司 |
杀微生物的喹啉(硫代)羧酰胺衍生物
|
|
CN107812006A
(zh)
*
|
2017-11-13 |
2018-03-20 |
全椒先奇医药科技有限公司 |
一种治疗急性肾衰药物组合物及其应用
|